Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714265 | 0.92 | SIGMAR1 (0.42) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5715052 | 0.92 | SMN1; SMN2 (0.49) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5714644 | 0.87 | HRH3 (0.41) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5715045 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL5714896 | 0.86 | MAPT (0.39) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5714332 | 0.86 | MAPT (0.38) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5715104 | 0.85 | CYP1A2 (0.41) | SMN1; SMN2ALDH1A1KDM4EMGLL | |
| SCHEMBL5713998 | 0.85 | SMN1; SMN2 (0.47) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5714194 | 0.84 | ALDH1A1 (0.44) | MAPTSMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL5714580 | 0.83 | MAPT (0.39) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | MAPT 4348/4885NPC1 624/4885RAB9A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.